recombinant

(redirected from Teriparatide)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

recombinant

Genetics
1. produced by the combining of genetic material from more than one origin
2. a chromosome, cell, organism, etc., the genetic makeup of which results from recombination

recombinant

[rē′käm·bə·nənt]
(genetics)
Any new cell, individual, or molecule that is produced in the laboratory by recombinant deoxyribonucleic acid technology or that arises naturally as a result of recombination.
References in periodicals archive ?
Romosozumab improves strength at the lumbar spine and hip in postmenopausal women with low bone mass compared with teriparatide.
In one, subjects were randomized to subcutaneous abaloparatide, teriparatide (Forteo) at its approved dose of 20 meg by daily subcutaneous injection, or placebo (see graphic).
Nausea, headaches and leg cramps are not infrequent in patients treated with teriparatide.
These identical initial cohorts were maintained by the model and simulated across both the teriparatide and no treatment arms for each replication.
Effects of Intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
In considering possible reasons for this combination's superiority over combined bisphosphonate and teriparatide, Leder said that teriparatide actually stimulates both bone formation and resorption and that denosumab may more completely block teriparatide-induced resorption while only partially interfering with the drug's stimulation of bone formation.
The DATA (Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis) trial is the first to study denosumab in combination with an anabolic agent.
either 20 [eth]-g/d teriparatide (TPTD, n=28) or 5 mg/y zoledronic acid
Additionally, according to the report, teriparatide therapy was started after pubic ramus fractures, 3 months later than the first fracture.
About two months after the device was implanted--and after the immune system's protective barrier had formed--wireless signals programmed the device to release daily doses of teriparatide.
The investigators made case studies of three high-cost drugs that were considered by all three agencies: ranibizumab (marketed as Lucentis in the United States); insulin glargine (Lantus), and teriparatide (Forteo).